OR WAIT 15 SECS
Solution addresses biomarkers, incorporates molecular information
PHILADELPHIA, June 19, 2006-SAS, the leader in business intelligence, today announced new genomic-analysis capabilities for its flagship life sciences offering, SAS® Drug Development. These new capabilities will make it easier for pharmaceutical companies to analyze genetic data and incorporate this analysis into new drug applications.
SAS Drug Development is a powerful data management and analysis solution for pharmaceutical, medical device and biotechnology firms. More than 90 processes for genomic and proteomic-specific molecular analyses-powered by JMP® software-are now incorporated into SAS Drug Development, addressing the areas of: